Syndax's CEO Michael Metzger talks about the approvals of Revuforj and Niktimvo, moving both into other settings, competition, and more

He describes being first to market in the menin inhibitor space and the advantage he believes that gives Syndax, and he highlights other recent data from the program. Plus, the immanent launch of Niktimvo, doing a deal with Royalty Pharma, and how he believes GVHD can be a substantial market.